榮昌生物AH股齊跌 2022年同比盈轉虧
格隆匯2月28日丨港股榮昌生物(9995.HK)盤中跌2.55%,報49.75港元;A股榮昌生物(688331.SH)跌0.38%,報73.95元,總市值402億元。榮昌生物發佈2022年度業績快報:營業總收入為79,410.61萬元,同比下滑44.33%;歸屬於母公司股東的淨利潤為-95,886.43萬元,較上年同期由盈轉虧。報吿期內,營業利潤、利潤總額、歸屬於母公司所有者的淨利潤、歸屬於母公司所有者的扣除非經常性損益的淨利潤同比減少,主要系除了上述營業收入同比減少之外,本年度商業化銷售投入團隊建設費用和學術推廣活動等增加,另各研發管線持續推進、研發費用大幅度增加。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.